news flash·2025-05-30 10:00Group 1 - The core point of the article is that the indirect controlling shareholder of Laimei Pharmaceutical, Guangtou Group, plans to increase capital in Guangtou Jinkong by using its 859 million shares of Zhongheng Group, which accounts for 25.94% of Zhongheng Group's total share capital [1] - This transaction is classified as a change in state-owned equity under the same control [1] - After the completion of the transaction, Guangtou Jinkong will become the indirect controlling shareholder of Laimei Pharmaceutical, while Zhongheng Group will remain the direct controlling shareholder [1] Group 2 - The actual controller of Laimei Pharmaceutical will still be the Guangxi State-owned Assets Supervision and Administration Commission [1] - The equity change is currently in the planning stage and requires approval from state-owned assets authorities and other legal procedures [1]